vs

Side-by-side financial comparison of Canaan Inc. (CAN) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $20.8M, roughly 1.3× Canaan Inc.). Canaan Inc. runs the higher net margin — -18.4% vs -71.0%, a 52.5% gap on every dollar of revenue.

Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

CAN vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.3× larger
ZYME
$27.6M
$20.8M
CAN
Higher net margin
CAN
CAN
52.5% more per $
CAN
-18.4%
-71.0%
ZYME

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
CAN
CAN
ZYME
ZYME
Revenue
$20.8M
$27.6M
Net Profit
$-3.8M
$-19.6M
Gross Margin
99.9%
Operating Margin
-15.9%
-80.1%
Net Margin
-18.4%
-71.0%
Revenue YoY
72.6%
Net Profit YoY
34.3%
EPS (diluted)
$-0.05
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAN
CAN
ZYME
ZYME
Q4 25
$20.8M
Q3 25
$13.8M
$27.6M
Q2 25
$11.4M
$48.7M
Q1 25
$27.1M
Q4 24
$31.0M
Q3 24
$10.2M
$16.0M
Q2 24
$4.8M
$19.2M
Q1 24
$10.0M
Net Profit
CAN
CAN
ZYME
ZYME
Q4 25
$-3.8M
Q3 25
$-1.5M
$-19.6M
Q2 25
$-11.9M
$2.3M
Q1 25
$-22.6M
Q4 24
$-23.5M
Q3 24
$-10.4M
$-29.9M
Q2 24
$-5.4M
$-37.7M
Q1 24
$-31.7M
Gross Margin
CAN
CAN
ZYME
ZYME
Q4 25
99.9%
Q3 25
99.9%
Q2 25
99.9%
Q1 25
Q4 24
Q3 24
99.9%
Q2 24
99.8%
Q1 24
Operating Margin
CAN
CAN
ZYME
ZYME
Q4 25
-15.9%
Q3 25
-27.0%
-80.1%
Q2 25
-45.5%
-1.4%
Q1 25
-94.5%
Q4 24
-71.6%
Q3 24
-77.2%
-213.8%
Q2 24
-193.9%
-222.9%
Q1 24
-376.9%
Net Margin
CAN
CAN
ZYME
ZYME
Q4 25
-18.4%
Q3 25
-11.0%
-71.0%
Q2 25
-104.4%
4.8%
Q1 25
-83.5%
Q4 24
-75.8%
Q3 24
-102.7%
-186.6%
Q2 24
-112.3%
-195.8%
Q1 24
-315.6%
EPS (diluted)
CAN
CAN
ZYME
ZYME
Q4 25
$-0.05
Q3 25
$-0.02
$-0.26
Q2 25
$-0.25
$0.03
Q1 25
$-0.30
Q4 24
$-0.32
Q3 24
$-0.39
Q2 24
$-0.49
Q1 24
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAN
CAN
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$64.8M
Total DebtLower is stronger
$6.2M
Stockholders' EquityBook value
$52.4M
$320.1M
Total Assets
$92.5M
$397.3M
Debt / EquityLower = less leverage
0.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAN
CAN
ZYME
ZYME
Q4 25
Q3 25
$64.8M
Q2 25
$98.3M
Q1 25
$76.2M
Q4 24
$66.1M
Q3 24
$122.4M
Q2 24
$71.0M
Q1 24
$114.8M
Total Debt
CAN
CAN
ZYME
ZYME
Q4 25
$6.2M
Q3 25
$6.2M
Q2 25
$6.2M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CAN
CAN
ZYME
ZYME
Q4 25
$52.4M
Q3 25
$44.7M
$320.1M
Q2 25
$33.8M
$334.5M
Q1 25
$325.0M
Q4 24
$338.8M
Q3 24
$43.6M
$367.0M
Q2 24
$56.8M
$406.2M
Q1 24
$438.0M
Total Assets
CAN
CAN
ZYME
ZYME
Q4 25
$92.5M
Q3 25
$81.7M
$397.3M
Q2 25
$78.0M
$408.4M
Q1 25
$425.5M
Q4 24
$463.1M
Q3 24
$69.3M
$487.2M
Q2 24
$73.7M
$515.6M
Q1 24
$553.8M
Debt / Equity
CAN
CAN
ZYME
ZYME
Q4 25
0.12×
Q3 25
0.14×
Q2 25
0.18×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAN
CAN
ZYME
ZYME
Operating Cash FlowLast quarter
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAN
CAN
ZYME
ZYME
Q4 25
Q3 25
$-31.4M
Q2 25
$12.1M
Q1 25
$-3.4M
Q4 24
$-41.5M
Q3 24
$-5.9M
Q2 24
$-25.0M
Q1 24
$-37.7M
Free Cash Flow
CAN
CAN
ZYME
ZYME
Q4 25
Q3 25
$-31.8M
Q2 25
$11.6M
Q1 25
$-3.4M
Q4 24
$-41.8M
Q3 24
$-6.8M
Q2 24
$-25.6M
Q1 24
$-37.9M
FCF Margin
CAN
CAN
ZYME
ZYME
Q4 25
Q3 25
-115.2%
Q2 25
23.7%
Q1 25
-12.6%
Q4 24
-134.8%
Q3 24
-42.4%
Q2 24
-133.0%
Q1 24
-377.5%
Capex Intensity
CAN
CAN
ZYME
ZYME
Q4 25
Q3 25
1.5%
Q2 25
1.1%
Q1 25
0.1%
Q4 24
1.0%
Q3 24
5.6%
Q2 24
3.1%
Q1 24
1.8%
Cash Conversion
CAN
CAN
ZYME
ZYME
Q4 25
Q3 25
Q2 25
5.21×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons